PERSONALISED APPROACH IN COMBINED TREATMENT OF CHOLANGIOCARCINOMA: A CASE REPORT OF HEALING FROM CHOLANGIOCELLULAR CARCINOMA AT STAGE IV
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
We describe a rare case of cure for poorly differentiated stage T4N1M0 cholangiocarcinoma with an atypical genetic mutation in the BRAF V600E gene. The 38-year-old patient underwent surgery at the National Surgical Institute for cholangiocellular carcinoma of the left lobe of the liver with invasion of the anterior abdominal wall, diaphragm, and pericardium. A left lobe liver resection with lymph node dissection and pericardial resection was performed. Adjuvant chemotherapy (GEMOX) was ineffective. Treatment with pembrolizumab also failed to improve the patient's condition. Molecular profiling of the tumor using next-generation sequencing revealed a mutation in the BRAF V600E gene. Targeted therapy with dabrafenib and trametinib, BRAF gene inhibitors, was initiated, resulting in a complete response. The patient has been free of tumor activity and signs of recurrence for two years. To our knowledge, this clinical case is the most detailed reported worldwide for stage IV cholangiocellular carcinoma treated with dabrafenib and trametinib.
Fields of Study & Subjects
Cholangiocarcinoma and Gallbladder Cancer Studies
Pediatric Hepatobiliary Diseases and Treatments
Colorectal Cancer Treatments and Studies
Publication details
- Journal / source
- BULLETIN OF SURGERY OF KAZAKHSTAN
- Volume
- 22
- Issue
- 1
- Pages
- 7–7
- Publication date
- 30 March 2026
- Language
- EN